These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 26773117)

  • 21. Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy.
    Aikawa NE; França IL; Ribeiro AC; Sallum AM; Bonfa E; Silva CA
    Vaccine; 2015 Jan; 33(5):604-9. PubMed ID: 25554240
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients.
    Kapetanovic MC; Saxne T; Nilsson JA; Geborek P
    Rheumatology (Oxford); 2007 Apr; 46(4):608-11. PubMed ID: 17114801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pneumococcal infections and vaccination in patients with systemic autoimmune and/or inflammatory diseases].
    Duchet-Niedziolka P; Hanslik T; Aouba A; Le Guern V; Guillevin L; Launay O;
    Presse Med; 2009 Feb; 38(2):243-50. PubMed ID: 19046848
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept.
    Mease PJ; Ritchlin CT; Martin RW; Gottlieb AB; Baumgartner SW; Burge DJ; Whitmore JB
    J Rheumatol; 2004 Jul; 31(7):1356-61. PubMed ID: 15229957
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune response to influenza vaccine and pneumococcal polysaccharide vaccine under IL-6 signal inhibition therapy with tocilizumab.
    Tsuru T; Terao K; Murakami M; Matsutani T; Suzaki M; Amamoto T; Nakashima H; Akiyama A; Nishimoto N
    Mod Rheumatol; 2014 May; 24(3):511-6. PubMed ID: 24252023
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduced risk of serious pneumococcal infections up to 10 years after a dose of pneumococcal conjugate vaccine in established arthritis.
    Nagel J; Jönsson G; Nilsson JÅ; Manuswin C; Englund M; Saxne T; Kapetanovic MC
    Vaccine; 2023 Jan; 41(2):504-510. PubMed ID: 36496283
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccine responses in patients with rheumatoid arthritis treated with certolizumab pegol: results from a single-blind randomized phase IV trial.
    Kivitz AJ; Schechtman J; Texter M; Fichtner A; de Longueville M; Chartash EK
    J Rheumatol; 2014 Apr; 41(4):648-57. PubMed ID: 24584918
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence of TNF-α blocker immunogenicity in psoriatic arthritis.
    Zisapel M; Zisman D; Madar-Balakirski N; Arad U; Padova H; Matz H; Maman-Sarvagyl H; Kaufman I; Paran D; Feld J; Litinsky I; Wigler I; Caspi D; Elkayam O
    J Rheumatol; 2015 Jan; 42(1):73-8. PubMed ID: 25399390
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum uric acid increases in patients with systemic autoimmune rheumatic diseases after 3 months of treatment with TNF inhibitors.
    Hasikova L; Pavlikova M; Hulejova H; Kozlik P; Kalikova K; Mahajan A; Herrmann M; Stiburkova B; Zavada J
    Rheumatol Int; 2019 Oct; 39(10):1749-1757. PubMed ID: 31363829
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Initiation of tumor necrosis factor α antagonists and risk of fractures in patients with selected rheumatic and autoimmune diseases.
    Kawai VK; Grijalva CG; Arbogast PG; Curtis JR; Solomon DH; Delzell E; Chen L; Ouellet-Hellstrom R; Herrinton L; Liu L; Mitchell EF; Stein CM; Griffin MR
    Arthritis Care Res (Hoboken); 2013 Jul; 65(7):1085-94. PubMed ID: 23281339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pneumococcal antibody levels after pneumovax in patients with rheumatoid arthritis on methotrexate.
    Coulson E; Saravanan V; Hamilton J; So KL; Morgan L; Heycock C; Rynne M; Kelly C
    Ann Rheum Dis; 2011 Jul; 70(7):1289-91. PubMed ID: 21515601
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor.
    Boyce EG; Halilovic J; Stan-Ugbene O
    Clin Ther; 2010 Sep; 32(10):1681-703. PubMed ID: 21194591
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Jackson LA; Gurtman A; Rice K; Pauksens K; Greenberg RN; Jones TR; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3585-93. PubMed ID: 23688527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of smoking and alcohol consumption on markers of systemic inflammation, immunoglobulin levels and immune response following pneumococcal vaccination in patients with arthritis.
    Roseman C; Truedsson L; Kapetanovic MC
    Arthritis Res Ther; 2012 Jul; 14(4):R170. PubMed ID: 22824238
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults.
    Musher DM; Manof SB; Liss C; McFetridge RD; Marchese RD; Bushnell B; Alvarez F; Painter C; Blum MD; Silber JL
    J Infect Dis; 2010 Feb; 201(4):516-24. PubMed ID: 20092407
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of methotrexate, anti-tumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis.
    Hua C; Barnetche T; Combe B; Morel J
    Arthritis Care Res (Hoboken); 2014 Jul; 66(7):1016-26. PubMed ID: 24339395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination.
    Bhorat AE; Madhi SA; Laudat F; Sundaraiyer V; Gurtman A; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    AIDS; 2015 Jul; 29(11):1345-54. PubMed ID: 25888646
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension.
    Keystone EC; Breedveld FC; van der Heijde D; Landewé R; Florentinus S; Arulmani U; Liu S; Kupper H; Kavanaugh A
    J Rheumatol; 2014 Jan; 41(1):5-14. PubMed ID: 24241487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A quality improvement intervention failed to significantly increase pneumococcal and influenza vaccination rates in immunosuppressed inflammatory arthritis patients.
    Murray K; Low C; O'Rourke A; Young F; Callanan I; Feeney E; Veale DJ
    Clin Rheumatol; 2020 Mar; 39(3):747-754. PubMed ID: 31820135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis.
    Winthrop KL; Silverfield J; Racewicz A; Neal J; Lee EB; Hrycaj P; Gomez-Reino J; Soma K; Mebus C; Wilkinson B; Hodge J; Fan H; Wang T; Bingham CO
    Ann Rheum Dis; 2016 Apr; 75(4):687-95. PubMed ID: 25795907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.